Celastrol (NSC 70931)

Catalog No.S1290 Synonyms: Tripterine

For research use only.

Celastrol (NSC 70931, Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.

Celastrol (NSC 70931) Chemical Structure

CAS No. 34157-83-0

Selleck's Celastrol (NSC 70931) has been cited by 9 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Other Proteasome Products

Biological Activity

Description Celastrol (NSC 70931, Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.
Features A potent antioxidant and anti-inflammatory drug.
Targets
20S proteasome [1]
(Cell-free assay)
2.5 μM
In vitro

Celastrol at 5 μM inhibits the chymotrypsin-like, PGPH-like, and trypsin-like activities of the purified 20S proteasome by 80%, 5%, and <1%, respectively, whereas at 10 μM, it inhibits these three proteasomal activities by ∼90%, 15%, and <1%, respectively. Celastrol significantly inhibits the proteasomal chymotrypsin activity in PC-3 cells in a concentration-dependent manner. Celastrol at 2.5 μM to 5 μM induces caspase-3 activity by 4.7-fold to 5.5-fold in PC-3 cells. Celastrol (5 μM) treated cells, the levels of the proteasome target proteins, IκB-α and Bax, are increased after 1 hour and further increased to its peak for 4 hours to 12 hours. Celastrol (2.5 μM) treatment induces proteasome inhibition by 40%, as shown by the decreased levels of chymotrypsin-like activity and increased accumulation of ubiquitinated proteins in LNCaP cells. Celastrol (2.5 μM) induces apoptosis in the Celastrol-treated LNCaP cells, as shown by increased levels of caspase-3 activity (up to 3.5-fold), PARP cleavage, and apoptotic morphology. [1] Celastrol (300 nM) is found to suppress LPS-induced production of TNF-alpha and IL-1beta by human monocytes and macrophages. Celastrol (100 nM) also decreases LPS-induced expression of class II MHC molecules by microglia. Celastrol strongly inhibits LPS and IFN-y-induced NO production with IC50 of 200 nM in macrophage lineage cells. Celastrol strongly inhibits TNF-α and IFN-γ-induced NO production with IC50 of 200 nM in endothelial cells. [2] Celastrol (2.5 μM) potentiates the apoptosis induced by TNF and chemotherapeutic agents and inhibits invasion, both regulated by NF-kappaB activation, in KBM-5 cells. Celastrol (2.5 μM) suppresses the expression of TNF induced the expression of gene products involved in antiapoptosis (IAP1, IAP2, Bcl-2, Bcl-XL, c-FLIP, and survivin), proliferation (cyclin D1 and COX-2), invasion (MMP-9), and angiogenesis (VEGF) in KBM-5 cells. Celastrol (5 μM) is found to inhibit the TNF-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 nuclear translocation and phosphorylation, and NF-kappaB-mediated reporter gene expression. [3] Celastrol inhibits proliferating of RPMI 8226, KATOIII, UM-SCC1, U251MG and MDA-MB-231 cells with IC50 of 0.52 μM, 0.54 μM, 0.76 μM, 0.69 μM and 0.67 μM, respectively. Celastrol (1 μM) inhibits growth of RPMI 8226 with a decrease in the levels of cyclin D1 and cyclin E, but concomitant increase in the levels of p21 and p27. Celastrol induces apoptosis in RPMI-8226 cells indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins. Celastrol (1 μM) suppresses Akt pathway and activates JNK kinase in RPMI-8226 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RAW264.7 MU\BcpRqcW6obHHtcYF1d3K7IHHzd4F6 NFrSPVgzPCCqcoO= MlG0RY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbjD0doVifGWmIEOgbJJ{KGKnZn;y[UBNWFNiY3jhcIxmdmenIHHzd4V{e2WmIHHmeIVzKDJ2IHjyd{BjgSCJcnnld5MhemWjZ3XueEBie3OjeTygTWM2OCB;IECuNlMh|ryPLh?= NXny[YxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG4NFkxPzZpPkGxPFA6ODd4PD;hQi=>
RAW264.7 MoXkRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? MX2yOEBpenN? M{TIV2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKE6ILXvhdJBiSiCjY4TpeoF1cW:wIITy[YF1\WRiMzDodpMh[mWob4LlJGxRWyClaHHscIVv\2ViYYPz[ZN{\WRiYX\0[ZIhOjRiaILzJIJ6KFOHQWCgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvOjdizszNMi=> MorXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF6MEmwO|YoRjFzOEC5NFc3RC:jPh?=
RPMI8226 NFTtSJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYjjeXVNT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPSUiyNlYh[2WubIOsJGlEPTBiPTCzJO69VS5? M1HsblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MU[0NVk4Lz5zOEG2OFE6PzxxYU6=
HeLa NVHXXZc{TnWwY4Tpc44h[XO|YYm= M4nKU2lvcGmkaYTpc44hd2ZiVF7GMYFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BjgSCVRVHQJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjF3IN88UU4> MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6NEG5NFYoRjF6OESxPVA3RC:jPh?=
RAW264.7 Mn7GSpVv[3Srb36gZZN{[Xl? Mkj4TY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDOSk1s[XCyYVKgZYN1cX[jdHnvckBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDifUBUTUGSIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlMh|ryPLh?= M{DIdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPVA3Lz5zOEi0NVkxPjxxYU6=
SH-SY5Y NGnTbW5HfW6ldHnvckBie3OjeR?= MmHIUoV2em:ycn;0[YN1cW:wIHHnZYlve3RiYnX0ZU1idXmub3nkJJBmeHSrZHWgNU01Oi2rbnT1Z4VlKHSxeHnjbZR6KGmwIHj1cYFvKFOKLWPZOXkh[2WubIOgZZN{\XO|ZXSgZZMhdGGldHH0[UBl\Wi7ZILv[4Vv[XOnIILlcIVie2VuIFXDOVAhRSByLkCzO|Y1KM7:TT6= MnryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzM{i4OVkoRjF7MUO4PFU6RC:jPh?=
HeLa NU\DUW1UTnWwY4Tpc44h[XO|YYm= M1u3V|IhcHK| MVvBcZBtcW[rY3H0bY9vKG:oIFjTSlEhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIlvKGi3bXHuJIhm[XRic3jvZ4sucW6mdXPl[EBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHfyZY52dGViZn;ycYF1cW:wIITy[YF1\WRiMTDodkBj\W[xcnWgbIVifCC|aH;jb{BkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgNkBpenNid3n0bI92fCC{ZXPveoVzgSC2aX3lJIJ6KGmvbYXuc4N6fG:laHXtbYNidCC|dHHpcolv\yxiRVO1NEA:KDFwMTFOwG0v NWS3dWwxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NFIxPTdpPkG5OVAzODV5PD;hQi=>
SK-N-SH NFjqZolEgXSxdH;4bYNqfHliYYPzZZk> NX;VdWRyPzJiaILz NXHUOm9qS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3TTEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDDR|UxKD1iMT62JO69VS5? M{LJ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUCyNFU4Lz5zOUWwNlA2PzxxYU6=
HeLa NVXLOGRETnWwY4Tpc44h[XO|YYm= M1jSSFMhcHK| NWHtTGVlSW2ybHnmbYNifGmxbjDv[kBJW0ZzIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCrbjDoeY1idiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJIdz[W63bHWg[o9zdWG2aX;uJJBz\XS{ZXH0[YQh\m:{IEOgbJJ{KGK7IHntcZVvd2O7dH;jbIVucWOjbDDzeIFqdmmwZzygSWM2OCB;IEKuOkDPxE1w M4jF[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUCyNFU4Lz5zOUWwNlA2PzxxYU6=
HeLa MoXPR5l1d3SxeHnjbZR6KGG|c3H5 M3jKc|czKGi{cx?= NEfsOZNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEOFNUCgQUA{KM7:TT6= NXvCZXN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NFIxPTdpPkG5OVAzODV5PD;hQi=>
HeLa NUL3N2Z6TnWwY4Tpc44h[XO|YYm= NXXs[5M2UW6qaXLpeIlwdiCxZjDOSk1s[XCyYVKgZYN1cX[rdImgbY4hcHWvYX6gTIVN[SClZXzsd{BjgSCVRVHQJJJmeG:{dHXyJIF{e2G7LDDJR|UxKD1iMD6xOUDPxE1w NH\HWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES2PVg5Pyd-MkC0Olk5QDd:L3G+
LNCAP NXLBfYtZSW62aYT1cY9zKGG|c3H5 MVPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOTlPBVEBk\WyuczygTWM2OCB;IEKuOUDPxE1w NH;E[mc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yO|U2Pid-MkC2Nlc2PTZ:L3G+
PC12 MoLNR5l1d3C{b4TlZ5RqfmViYYPzZZk> M1L4SWN6fG:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RidD3CVGgucW6mdXPl[EBk\WyuIHThcYFo\SCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSxiSVO1NEA:KDNwMUWg{txONg>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{N{W1Okc,OjB4Mke1OVY9N2F-
PC12 NGT5bm5EgXSxcILveIVkfGm4ZTDhd5NigQ>? MlPPNU43KHWP MYHDfZRweHKxdHXjeIl3\SCjY4Tpeol1gSCjZ3HpcpN1KHRvQmDIMYlv\HWlZXSgZ4VtdCCmYX3h[4UhcW5icnH0JHBEOTJiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[XRiMT62JJVO MnrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4Mke1OVYoRjJyNkK3OVU3RC:jPh?=
THP1 M3TmXGFxd3C2b4Ppd{Bie3OjeR?= MkXLNlQhcHK| NVP0ZoFWUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBVWkGLTD3y[ZNqe3SjboSgbJVu[W5iVFjQNUBk\WyuczDh[pRmeiB{NDDodpMh[nliYX7u[Zhqdi2YIIP0ZYlvcW6pLDDFR|UxKD1iMUWg{txONg>? NUnYc5FrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OlQ{PDJpPkKwPFY1OzR{PD;hQi=>
293T MknQSpVv[3Srb36gZZN{[Xl? M3[1clMxKG2rboO= NVjuVFBbUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBPTi2tYYDwZWIh[WO2aY\heIlwdiCrbjDoeY1idiB{OUPUJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOzBibXnud{Bnd2yub4fl[EBjgSC2cnXheIVlKHerdHigUHBUKG[xcjC2JIhzeyCkeTDkeYFtNWy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUCgQUAxNjF5IN88UU4> MoT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OUOwNFQoRjJzM{mzNFA1RC:jPh?=
293T NGXCOVdEgXSxdH;4bYNqfHliYYPzZZk> MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCyPVNVKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygTWM2OCB;IECuOlch|ryPLh?= MnewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OUOwNFQoRjJzM{mzNFA1RC:jPh?=
RAW264 M3XzVmZ2dmO2aX;uJIF{e2G7 M1nEc|I1KGi{cx?= M4XrNmlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiCrbjDtc5V{\SCUQWeyOlQh[2WubIOgZYZ1\XJiMkSgbJJ{ NV7PU25uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPVMxODRpPkKxN|k{ODB2PD;hQi=>
NCI-H460 MorHR5l1d3SxeHnjbZR6KGG|c3H5 MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkBwfmW{bnnnbJQhcW6ldXLheIlwdiCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxNk4{KM7:TT6= NV7VTlJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFI4PjVpPkKxPVQzPzZ3PD;hQi=>
RAW264.7 NHTzcHBCdnSraX7mcIFudWG2b4L5JIF{e2G7 MkTLNlQhcHK| M33jVGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDOU{Bxem:mdXP0bY9vKGGodHXyJFI1KGi{czDifUBIemmnc4OgdoVi\2WwdDDt[ZRpd2RuIFnDOVAhRSBzIN88UU4> MmrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7N{i2O|YoRjJzOUe4Olc3RC:jPh?=
RAW264.7 NFPFW3BCdnSraX7mcIFudWG2b4L5JIF{e2G7 NXfXZ4xwOjRiaILz NIHZPGhCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25iYX\0[ZIhOjRiaILzJIJ6KGe{aXXzd{Bie3OjeTygTWM2OCB;IEGg{txONg>? NH75dJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyOFA{Oyd-MkKwNlQxOzN:L3G+
RAW264.7 M2nL[mZ2dmO2aX;uJIF{e2G7 NETucZAyQCCqcoO= M2DjcWlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhVk[tYYDwZWIh[WO2aY\heIlwdiC2cnHud4Zm[3SnZDDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjZoTldkAyQCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6yJO69VS5? MnXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MEWwNlAoRjJ{N{C1NFIxRC:jPh?=
spleen adherent cells MVLBcpRq[XK2aILpeIlkKGG|c3H5 MVGyNFAhfWd? NYKyVHJFSW62aXHyeIhzcXSrYzDl[oZm[3RiaX6gUIV4cXNicnH0JIFlcnW4YX70MYlv\HWlZXSgZZJ1cHKrdHnzJI1w\GWuIIPwcIVmdiCjZHjldoVvfCClZXzsd{Bz\XO2aX31cIF1\WRid3n0bEB{d26rY3H0[YQhVXSkIIDvd5QhcXOxbHH0bY9vKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBES1J{IHX4dJJme3Orb36gZZQhOjByIIXnMEBqeCC|dHHyeIlv\yCocn;tJIFzfGi{aYTpd{BwdnOndDDhcoQh[2:wdHnueYVlKHWwaX70[ZJzfXC2ZXSgeY51cWx? M3r3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEW0NVk{Lz5{Mki1OFE6OzxxYU6=
spleen adherent cells MljiRY51cWG{dHjybZRq[yCjc4PhfS=> MnfrNlAxKHWp MVjBcpRq[XK2aILpeIlkKGWoZnXjeEBqdiCOZYfpd{Bz[XRiYXTqeZZidnRvaX7keYNm\CCjcoTodol1cXNibX;k[Ywhe3CuZXXuJIFlcGW{ZX70JINmdGy|IILld5RqdXWuYYTl[EB4cXSqIIPvcolk[XSnZDDNeIIheG:|dDDpd49t[XSrb36gZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFfSU{9MSyCycn;keYN1cW:wIHH0JFIxOCC3ZzygbZAhe3SjcoTpcoch\nKxbTDhdpRpemm2aYOgc45{\XRiYX7kJINwdnSrboXl[EB2dmmwdHXydpVxfGWmIIXueIk> NIXhRZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NYTMbFFUSW62aXHyeIhzcXSrYzDhd5NigQ>? NYfLO3JQOjByIIXn NG\lUXhCdnSrYYL0bJJqfGmlIHXm[oVkfCCrbjDM[ZdqeyC{YYSgZYRrfX[jboStbY5lfWOnZDDhdpRpemm2aYOgcY9l\Wxic4Ds[YVvKGGmaHXy[Y51KGOnbHzzJJJme3SrbYXsZZRm\CC5aYToJJNwdmmlYYTl[EBOfGJicH;zeEBqe2:uYYTpc44h[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJG1EWDFicILv[JVkfGmxbjDheEAzODBidXesJIlxKHO2YYL0bY5oKG[{b32gZZJ1cHKrdHnzJI9ve2W2IHHu[EBkd262aX71[YQhfW6rboTldpJ2eHSnZDD1cpRqdA>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3NEG5N{c,OjJ6NUSxPVM9N2F-
spleen adherent cells M1zEUWFvfGmjcoTodol1cWNiYYPzZZk> Mnz6NlAxKHWp M125[GFvfGmjcoTodol1cWNiZX\m[YN1KGmwIFzle4l{KHKjdDDh[Ip2fmGwdD3pcoR2[2WmIHHyeIhzcXSrczDtc4RmdCC|cHzl[Y4h[WSqZYLlcpQh[2WubIOgdoV{fGmvdXzheIVlKHerdHigd49vcWOjdHXkJG11[iCyb4P0JIl{d2yjdHnvckBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gVmFPXEWVIIDyc4R2[3Srb36gZZQhOjByIIXnMEBqeCC|dHHyeIlv\yCocn;tJIFzfGi{aYTpd{BwdnOndDDhcoQh[2:wdHnueYVlKHWwaX70[ZJzfXC2ZXSgeY51cQ>? NFj4fJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NGf0TWhCdnSrYYL0bJJqfGmlIHHzd4F6 Mn63NlAxKHWp NUDpNol4SW62aXHyeIhzcXSrYzDl[oZm[3RiaX6gUIV4cXNicnH0JIFlcnW4YX70MYlv\HWlZXSgZZJ1cHKrdHnzJI1w\GWuIIPwcIVmdiCjZHjldoVvfCClZXzsd{Bz\XO2aX31cIF1\WRid3n0bEB{d26rY3H0[YQhVXSkIIDvd5QhcXOxbHH0bY9vKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBVVk[jbIDoZUBxem:mdXP0bY9vKGG2IEKwNEB2\yxiaYCgd5RienSrbneg[pJwdSCjcoTodol1cXNib37z[ZQh[W6mIHPvcpRqdnWnZDD1colvfGW{coXweIVlKHWw M4Tp[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEW0NVk{Lz5{Mki1OFE6OzxxYU6=
spleen adherent cells M4nxOWFvfGmjcoTodol1cWNiYYPzZZk> MXKyNFAhfWd? NF[1dVdCdnSrYYL0bJJqfGmlIHXm[oVkfCCrbjDM[ZdqeyC{YYSgZYRrfX[jboStbY5lfWOnZDDhdpRpemm2aYOgcY9l\Wxic4Ds[YVvKGGmaHXy[Y51KGOnbHzzJJJme3SrbYXsZZRm\CC5aYToJJNwdmmlYYTl[EBOfGJicH;zeEBqe2:uYYTpc44h[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGNEWjNiZYjwdoV{e2mxbjDheEAzODBidXesJIlxKHO2YYL0bY5oKG[{b32gZZJ1cHKrdHnzJI9ve2W2IHHu[EBkd262aX71[YQhfW6rboTldpJ2eHSnZDD1cpRqdA>? MlfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUSxPVMoRjJ{OEW0NVk{RC:jPh?=
spleen adherent cells MVTBcpRq[XK2aILpeIlkKGG|c3H5 NVjj[JRwOjByIIXn M3;oN2FvfGmjcoTodol1cWNiZX\m[YN1KGmwIFzle4l{KHKjdDDh[Ip2fmGwdD3pcoR2[2WmIHHyeIhzcXSrczDtc4RmdCC|cHzl[Y4h[WSqZYLlcpQh[2WubIOgdoV{fGmvdXzheIVlKHerdHigd49vcWOjdHXkJG11[iCyb4P0JIl{d2yjdHnvckBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gR2NTPiCneIDy[ZN{cW:wIHH0JFIxOCC3ZzygbZAhe3SjcoTpcoch\nKxbTDhdpRpemm2aYOgc45{\XRiYX7kJINwdnSrboXl[EB2dmmwdHXydpVxfGWmIIXueIlt NGSwXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NGnTO4lCdnSrYYL0bJJqfGmlIHHzd4F6 MmXwNlAxKHWp MYPBcpRq[XK2aILpeIlkKGWoZnXjeEBqdiCOZYfpd{Bz[XRiYXTqeZZidnRvaX7keYNm\CCjcoTodol1cXNibX;k[Ywhe3CuZXXuJIFlcGW{ZX70JINmdGy|IILld5RqdXWuYYTl[EB4cXSqIIPvcolk[XSnZDDNeIIheG:|dDDpd49t[XSrb36gZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFPYR3IyKGW6cILld5Nqd25iYYSgNlAxKHWpLDDpdEB{fGG{dHnu[{Bnem:vIHHyeIhzcXSrczDvcpNmfCCjbnSgZ49vfGmwdXXkJJVvcW62ZYLyeZB1\WRidX70bYw> NFLwfoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NXi1SZk6SW62aXHyeIhzcXSrYzDhd5NigQ>? M{XYS|IxOCC3Zx?= MU\BcpRq[XK2aILpeIlkKGWoZnXjeEBqdiCOZYfpd{Bz[XRiYXTqeZZidnRvaX7keYNm\CCjcoTodol1cXNibX;k[Ywhe3CuZXXuJIFlcGW{ZX70JINmdGy|IILld5RqdXWuYYTl[EB4cXSqIIPvcolk[XSnZDDNeIIheG:|dDDpd49t[XSrb36gZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFPYR3IzKGW6cILld5Nqd25iYYSgNlAxKHWpLDDpdEB{fGG{dHnu[{Bnem:vIHHyeIhzcXSrczDvcpNmfCCjbnSgZ49vfGmwdXXkJJVvcW62ZYLyeZB1\WRidX70bYw> NHTpfYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NVfzOGMzSW62aXHyeIhzcXSrYzDhd5NigQ>? M1vKTFIxOCC3Zx?= MYrBcpRq[XK2aILpeIlkKGWoZnXjeEBqdiCOZYfpd{Bz[XRiYXTqeZZidnRvaX7keYNm\CCjcoTodol1cXNibX;k[Ywhe3CuZXXuJIFlcGW{ZX70JINmdGy|IILld5RqdXWuYYTl[EB4cXSqIIPvcolk[XSnZDDNeIIheG:|dDDpd49t[XSrb36gZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFPYR3I1KGW6cILld5Nqd25iYYSgNlAxKHWpLDDpdEB{fGG{dHnu[{Bnem:vIHHyeIhzcXSrczDvcpNmfCCjbnSgZ49vfGmwdXXkJJVvcW62ZYLyeZB1\WRidX70bYw> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3NEG5N{c,OjJ6NUSxPVM9N2F-
spleen adherent cells M1W5bWZ2dmO2aX;uJIF{e2G7 NGLKfZMzODBidXe= M3nZZWlv[3KnYYPlJIlvKEOFUkGg[ZhxemW|c3nvckBqdiCOZYfpd{Bz[XRiYXTqeZZidnRvaX7keYNm\CCjcoTodol1cXNibX;k[Ywhe3CuZXXuJIFlcGW{ZX70JINmdGy|IILld5RqdXWuYYTl[EB4cXSqIIPvcolk[XSnZDDNeIIheG:|dDDpd49t[XSrb36gZZQhOjByIIXnMEBqeCC|dHHyeIlv\yCocn;tJIFzfGi{aYTpd{BwdnOndDDhcoQh[2:wdHnueYVlKHWwaX70[ZJzfXC2ZXSgeY51cWxic4T1[Jkh\W6mIHL5JJFRS1JicnXsZZRqfmViYnHz[Yxqdg>? M3\XPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEW0NVk{Lz5{Mki1OFE6OzxxYU6=
spleen adherent cells M1HWbGFvfGmjcoTodol1cWNiYYPzZZk> MWOyNFAhfWd? MlWzRY51cWG{dHjybZRq[yCnZn\lZ5QhcW5iTHX3bZMhemG2IHHkbpV3[W62LXnu[JVk\WRiYYL0bJJqfGm|IH3v[IVtKHOybHXlckBi\GincnXueEBk\WyuczDy[ZN1cW23bHH0[YQhf2m2aDDzc45q[2G2ZXSgUZRjKHCxc4SgbZNwdGG2aX;uJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDJUE0y[mW2YTDwdo9lfWO2aX;uJIF1KDJyMDD1[{whcXBic4ThdpRqdmdiZoLvcUBienSqcnn0bZMhd26|ZYSgZY5lKGOxboTpcpVm\CC3bnnueIVzenWydHXkJJVv MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3NEG5N{c,OjJ6NUSxPVM9N2F-
spleen adherent cells NXvaVFVTSW62aXHyeIhzcXSrYzDhd5NigQ>? NV\2dVk5OjByIIXn NG\qS2dCdnSrYYL0bJJqfGmlIHXm[oVkfCCrbjDM[ZdqeyC{YYSgZYRrfX[jboStbY5lfWOnZDDhdpRpemm2aYOgcY9l\Wxic4Ds[YVvKGGmaHXy[Y51KGOnbHzzJJJme3SrbYXsZZRm\CC5aYToJJNwdmmlYYTl[EBOfGJicH;zeEBqe2:uYYTpc44h[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGNEWjViZYjwdoV{e2mxbjDheEAzODBidXesJIlxKHO2YYL0bY5oKG[{b32gZZJ1cHKrdHnzJI9ve2W2IHHu[EBkd262aX71[YQhfW6rboTldpJ2eHSnZDD1cpRqdA>? NEPl[Jg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
spleen adherent cells NV3MNIgyTnWwY4Tpc44h[XO|YYm= MmC2NlQhcHK| M4PuXWlv[3KnYYPlJIlvKEOFUkGgdJJwfGWrbjDzeZJn[WOnIHX4dJJme3Orb36gbY4he2:waXPheIVlKE22Yj3zeIlufWyjdHXkJJNxdGWnbjDh[IhmemWwdDDj[YxteyCrc3;sZZRm\CCocn;tJGxmf2m|IILheEBi\Gq3dnHueE1qdmS3Y3XkJIFzfGi{aYTpd{Bud2SnbDDwdoUucW6ldXLheIVlKHerdHigNE4yKHSxIECuN{B2VSClb33wc5Vv\CCkZX\vdoUhe3SrbYXsZZRqd25id3n0bEB{d26rY3H0[YQhVXSkIH\vdkAzPCCqcoOgZpkh\myxdzDjfZRwdQ>? NIHxOlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1OFE6Oyd-MkK4OVQyQTN:L3G+
RAW264.7 NGLmVoNCdnSraX7mcIFudWG2b4L5JIF{e2G7 M3rqeFI1KGi{cx?= NVfEPWdbSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJG5QKHC{b3T1Z5Rqd25iYX\0[ZIhOjRiaILzJIJ6KEe{aXXzd{Bu\XSqb3SsJGlEPTBiPTCxJO69VS5? Ml7nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMke4PFYoRjJ|MUK3PFg3RC:jPh?=
RAW264.7 M{jBNWFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? NYLRZ3hMOjRiaILz M4rTPGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDUUmZidHCqYTDwdo9lfWO2aX;uJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hOC56IN88UU4> M1LWdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkO0OFA4Lz5{M{KzOFQxPzxxYU6=
RAW264.7 M2PjSWFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? M3e4R|I1KGi{cx?= M2LFZ2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDubZRzcWNib4jp[IUh\2WwZYLheIlwdiCrbnP1ZoF1\WRiZn;yJFI1KGi{czygTWM2OCB;IEGg{txONg>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ|NESwO{c,OjN{M{S0NFc9N2F-
RAW264.7 MXPBcpRqcW6obHHtcYF1d3K7IHHzd4F6 Mo\3RY51cS2rbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDubZRzcWNib4jp[IUheHKxZIXjeIlwdiCkeTDHdolme3NicnXhZ5Rqd25iYnHz[YQhdWW2aH;kMEBKSzVyIE2gNUDPxE1w NWXkTG9oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N|c{PjNpPkK1OlM4OzZ|PD;hQi=>
MCF7 M2LIcmN6fG:2b4jpZ4l1gSCjc4PhfS=> MXu3NkBpenN? Mn3oR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVL2DNV{Bie3OjeTygTWM2OCB;IECuNVU{KM7:TT6= M37UOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W2Nlk6Lz5{NUe1OlI6QTxxYU6=
MCF7 NU\mWJhyTnWwY4Tpc44h[XO|YYm= NH3yZXIzPCCqcoO= M2\xT2lvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDwRYt1KGSnZ4Lh[IF1cW:wIHH0JFUhfGmvZYOgTWM2OCCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NUnwfXR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVYzQTlpPkK1O|U3Ojl7PD;hQi=>
MCF7 NYK0dHRbTnWwY4Tpc44h[XO|YYm= MkjkNlQhcHK| M1XGV2lvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDI[ZIzKGSnZ4Lh[IF1cW:wIHH0JFUhfGmvZYOgTWM2OCCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NkK5PUc,OjV5NU[yPVk9N2F-
MCF7 MXzGeY5kfGmxbjDhd5NigQ>? M4HoNFI1KGi{cx?= MmPKTY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IFPkb|Yh\GWpcnHkZZRqd25iYYSgOUB1cW2nczDJR|UxKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NkK5PUc,OjV5NU[yPVk9N2F-
MCF7 NHvMTGlHfW6ldHnvckBie3OjeR?= MmHjNlQhcHK| NH[5S2NKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgVoFnKGSnZ4Lh[IF1cW:wIHH0JFUhfGmvZYOgTWM2OCCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NH;OUVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OlI6QSd-MkW3OVYzQTl:L3G+
MCF7 NXjrTGZoTnWwY4Tpc44h[XO|YYm= MnvnNlQhcHK| M2XrSWNp[W6pZTDpckBE\GN|NzDlfJBz\XO|aX;uJIlvKGi3bXHuJG1ETjdiY3XscJMh[XRiNTD0bY1meyCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M3z4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W2Nlk6Lz5{NUe1OlI6QTxxYU6=
MCF7 MkjWSpVv[3Srb36gZZN{[Xl? NVzxWlk5OjRiaILz NUfT[VlbS2ijbnflJIlvKHB{MzDlfJBz\XO|aX;uJIlvKGi3bXHuJG1ETjdiY3XscJMh[XRiNTD0bY1meyCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NkK5PUc,OjV5NU[yPVk9N2F-
MCF7 MYDGeY5kfGmxbjDhd5NigQ>? M{DtO|I1KGi{cx?= NViyWohTUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJIRqe3K3cITpc44hd2ZiaX70[ZJi[3Srb36ge4l1cCCFZHOzO{BifCB3IITpcYV{KEmFNUCgZYZ1\XJiMkSgbJJ{KGK7IHPvMYludXWwb4Dy[YNqeGm2YYTpc44h[XO|YYm= MnjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NU[yPVkoRjJ3N{W2Nlk6RC:jPh?=
MCF7 M{DTSWZ2dmO2aX;uJIF{e2G7 NFHoNmszPCCqcoO= NGXIWWRKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[Il{enWydHnvckBw\iCrboTldoFkfGmxbjD3bZRpKHB{MzDheEA2KHSrbXXzJGlEPTBiYX\0[ZIhOjRiaILzJIJ6KGOxLXntcZVvd3C{ZXPpdIl1[XSrb36gZZN{[Xl? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NkK5PUc,OjV5NU[yPVk9N2F-
SGC7901 NEH6eotCdnSrY3HuZ4VzKGG|c3H5 M1yxO|Q5KGi{cx?= NUL3TXlySW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHNISzd7MEGgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC|dYL2bZZidCCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zNTFOwG0v Mnm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUK5OlYoRjJ3OEGyPVY3RC:jPh?=
SMMC7721 M{HDT2FvfGmlYX7j[ZIh[XO|YYm= NWXXeZhMPDhiaILz NYm3[phXSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHNOVUN5N{KxJINmdGy|IHHzd4V{e2WmIHHzJINmdGxic4Xyeol3[WxiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwNUig{txONg>? NYD0N4lsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVI6PjZpPkK1PFEzQTZ4PD;hQi=>
MGC803 MnzpRY51cWOjbnPldkBie3OjeR?= MnLHOFghcHK| M1G1UGFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB{fXK4aY\hcEBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNU42PSEQvF2u MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMkm2Okc,OjV6MUK5OlY9N2F-
HepG2 NYDqNFNiSW62aXPhcoNmeiCjc4PhfS=> NFXQSVc1QCCqcoO= M37MdmFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC0MlAyKM7:TT6= MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUK5OlYoRjJ3OEGyPVY3RC:jPh?=
A549 M1G5cWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MUW0PEBpenN? MljRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDwZYNtcXSjeHXsMZJme2m|dHHueEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi5yMTFOwG0v MmjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4NEezOlkoRjJ5NkS3N|Y6RC:jPh?=
A549 M{G2N2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MlyxOFghcHK| NFToe2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjB{IN88UU4> NHTHPWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[0O|M3QSd-Mke2OFc{Pjl:L3G+
MCF7 MoDwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1zPfFQ5KGi{cx?= NHLDemdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjF|IN88UU4> NGW3RnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[0O|M3QSd-Mke2OFc{Pjl:L3G+
PANC1 M4jkN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3jp[|Q5KGi{cx?= M3zGeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFHOR|Eh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjR6IN88UU4> M365fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkS3N|Y6Lz5{N{[0O|M3QTxxYU6=
LNCAP M1\WNWZ2dmO2aX;uJIF{e2G7 NFn1em82KHWP Mm\JNlQhcHK| M1fxT2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiQWKgbY4hcHWvYX6gUG5ESVBiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhTEiWLXnu[JVk\WRicnXj[ZB1d3JidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGG2IEWgeW0h[W[2ZYKgNlQhcHK|IHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|EoRjJ5OUm0O|MyRC:jPh?=
A549 M4\jdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUG2JIRigXN? M3fYcGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMhdWWjc4Xy[YQh\X[ncomgNkBpenNib4\ldkA3KGSjeYOgZpkhdGm4ZTDj[YxtKGmvYXfpcoch[mG|ZXSgcYV1cG:mLDDJR|UxKD1iMD62PUDPxE1w MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ{MUm0N{c,Ojh4MkG5OFM9N2F-
HEK293 MofVSpVv[3Srb36gZZN{[Xl? NUn1RmNzOTBidV2= M{\k[FIxKG2rboO= NGrjU5pKdmirYnn0bY9vKG:oIFfhcJBp[W9iaX70[ZJi[3Srb36ge4l1cCCJRmCt[pV{\WRiUlfTNVchMHWwa37ve44hd3KrZ3nuLUBl\Wy2YV6gcZV1[W62IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hWkeVMUeg[IVtfGGQIH31eIFvfCCub3PhcIl7[XSrb36gZZQh[3m2b4DsZZNuKGG2IEGwJJVOKHWyIITvJFIxKG2rboOgZpkh[2:wZn;jZYwhdWmlcn;zZ49xcWNiYX7hcJl{cXN? NUfIWIU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NlE6PDNpPkK4OlIyQTR|PD;hQi=>
HEK293 MUnGeY5kfGmxbjDhd5NigQ>? M2HpWVExOCC3TR?= MWi1JI1qdnN? NWXCemdvUW6qaXLpeIlwdiCxZjDHZYxxcGFyIHnueIVz[WO2aX;uJJdqfGhiR1\QMYZ2e2WmIGLHV|E4KCi3bnvuc5dvKG:{aXfpckkh\GWudHHOJI12fGGwdDDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFKJU{G3JIRmdHSjTjDteZRidnRibH;jZYxqgmG2aX;uJIF1KGO7dH;wcIF{dSCjdDCxNFAhfU1idYCgeI8hPSCvaX7zJIJ6KGOxbn\vZ4FtKG2rY4Lvd4NweGmlIHHuZYx6e2m| MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MkG5OFMoRjJ6NkKxPVQ{RC:jPh?=
HEK293 MYXGeY5kfGmxbjDhd5NigQ>? MmXaNVAhfU1? M2HIUVUhdWmwcx?= NWPOUVZlUW6qaXLpeIlwdiCxZjDHZYxxcGGxIHnueIVz[WO2aX;uJJdqfGhiR1\QMYZ2e2WmIGLHV|E4KCi3bnvuc5dvKG:{aXfpckkh\GWudHHOJI12fGGwdDDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFKJU{G3JIRmdHSjTjDteZRidnRibH;jZYxqgmG2aX;uJIF1KGO7dH;wcIF{dSCjdDCxNEB2VSC3cDD0c{A2KG2rboOgZpkh[2:wZn;jZYwhdWmlcn;zZ49xcWNiYX7hcJl{cXN? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ{MUm0N{c,Ojh4MkG5OFM9N2F-
MIAPaCa2 MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVq3NkBpenN? MnTERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPSVHQZWNiOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE41PiEQvF2u MmHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEiyPFEoRjJ6Nki4NlgyRC:jPh?=
SKBR3 NH\rSGFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVe1[|RMPzJiaILz MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONQmKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkeyJO69VS5? NI\SSlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI5OSd-Mki2PFgzQDF:L3G+
SKOV3 MmPvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NE\GTFE4OiCqcoO= M37LZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vPWlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuNVYh|ryPLh?= NWewZmlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFgzQDFpPkK4Olg5OjhzPD;hQi=>
MDA-MB-231 MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MnPiO|IhcHK| MmfTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyNjN{IN88UU4> M4f5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Nki4NlgyLz5{OE[4PFI5OTxxYU6=
A549 MX\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NILheXQ4OiCqcoO= NG\0e3pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuOVYh|ryPLh?= NI\OV|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI5OSd-Mki2PFgzQDF:L3G+
BJ MYfDfZRwfG:6aXPpeJkh[XO|YYm= NFuzTIs4OiCqcoO= NUX6OWZMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{Lke0JO69VS5? M4LkUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Nki4NlgyLz5{OE[4PFI5OTxxYU6=
NCI-H460 M1vSU2Z2dmO2aX;uJIF{e2G7 M1HEfVEhfU1? NFXZeXEyOiCqcoO= MU\BZ5RqfmG2aX;uJI9nKEiVRkGgbY4hcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOgeZBz\We3bHH0bY9vKG:oIFjTVFI2KHC{b4TlbY4hdGW4ZXzzJIF1KDFidV2gZYZ1\XJiMUKgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NIHzPGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezO|kyPid-Mki3N|c6OTZ:L3G+
NCI-H460 MVXGeY5kfGmxbjDhd5NigQ>? M1r0XVEhfU1? M{K4b|EzKGi{cx?= NVHYTmhlSWO2aY\heIlwdiCxZjDIV2YyKGmwIHj1cYFvKE6FST3IOFYxKGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBJW1B5MDDwdo91\WmwIHzleoVteyCjdDCxJJVOKGGodHXyJFEzKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd|N{mxOkc,Ojh5M{e5NVY9N2F-
NCI-H1299 NH\ueoZEgXSxdH;4bYNqfHliYYPzZZk> NV;2dXZ4S3m2b4TvfIlkcXS7IHnuJIh2dWGwIF7DTU1JOTJ7OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImsJGlEPTBiPTCxJO69VS5? M4OxRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W0OFcxLz5{OEe1OFQ4ODxxYU6=
BCP-ALL MX;DfZRwfG:6aXPpeJkh[XO|YYm= NXXJNW5JS3m2b4TvfIlkcXS7IHnuJIh2dWGwIFLDVE1CVExiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7LDDJR|UxKD1iMTFOwG0v NXvXNHZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVQ1PzBpPkK4O|U1PDdyPD;hQi=>
T-ALL Ml2xR5l1d3SxeHnjbZR6KGG|c3H5 MXrDfZRwfG:6aXPpeJkhcW5iaIXtZY4hXC2DTFygZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5MEBKSzVyIE2gNUDPxE1w NUj3T|NFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVQ1PzBpPkK4O|U1PDdyPD;hQi=>
Daudi MULDfZRwfG:6aXPpeJkh[XO|YYm= M1fQ[WN6fG:2b4jpZ4l1gSCrbjDoeY1idiCGYYXkbUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJktKEmFNUCgQUAyKM7:TT6= NGr0XW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe1OFQ4OCd-Mki3OVQ1PzB:L3G+
HL60 M3[4dGN6fG:2b4jpZ4l1gSCjc4PhfS=> M2O2R2N6fG:2b4jpZ4l1gSCrbjDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUwhUUN3MDC9JFEh|ryPLh?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd3NES3NEc,Ojh5NUS0O|A9N2F-
TC32 NGfkNFFyUFSVIHHzd4F6 NGPPToRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= M4XDXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY NVrwcHpWeUiWUzDhd5NigQ>? M{LUVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MnnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NHL3dm5yUFSVIHHzd4F6 MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= M4PPdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 M{LNN5FJXFNiYYPzZZk> NEHMdIJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MUfxTHRUKGG|c3H5 NX;TV2Y5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> M1PXWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 M2P6OJFJXFNiYYPzZZk> Mn6ydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| M13jTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MmjadWhVWyCjc4PhfS=> MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NFTEcnpyUFSVIHHzd4F6 MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH NXLxS2tmeUiWUzDhd5NigQ>? Ml22dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NX7sZZB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 MWDxTHRUKGG|c3H5 Mn3kdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 MnvydWhVWyCjc4PhfS=> NUHEVWhkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz NITiXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 NH7nO2RyUFSVIHHzd4F6 NIfnTZFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= NEP2bHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 MmP5dWhVWyCjc4PhfS=> MnjmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? Ml\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NEPHfY9yUFSVIHHzd4F6 M3SzU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NF7Hc3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MX;xTHRUKGG|c3H5 M4X2ZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NVnSOYM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) MYnxTHRUKGG|c3H5 M37hR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= NVHSdI1HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 M2T6V5FJXFNiYYPzZZk> Mn;TdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NFW2N3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NF\RT5pyUFSVIHHzd4F6 M{XHSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| M1[xWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MXfxTHRUKGG|c3H5 Mk\XdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR|IHPlcIx{ NYCw[2UxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MoHNdWhVWyCjc4PhfS=> M4HlcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MVLxTHRUKGG|c3H5 MkXydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>? NUHOcIFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NFXtdIhyUFSVIHHzd4F6 NEHmcVZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>? M3f6NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 MU\xTHRUKGG|c3H5 M4DXXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGxCVi13IHPlcIx{ NXq2S3g2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY NHTCSHVyUFSVIHHzd4F6 NXLrfJhOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 NYHIfYhReUiWUzDhd5NigQ>? MkDidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>? NV7V[IVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 MoHxdWhVWyCjc4PhfS=> MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{ Mkn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NWixdIQ1eUiWUzDhd5NigQ>? NVznfJR1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 M4C0NJFJXFNiYYPzZZk> NXr6OXA5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? M37EfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) M2DQbZFJXFNiYYPzZZk> MlfJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM> NWHERZlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells NWjIcod{eUiWUzDhd5NigQ>? NV3aOFhReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG|dDDj[Yxtew>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
U-2 OS MVjxTHRUKGG|c3H5 Ml\IdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{ MoiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MmKwdWhVWyCjc4PhfS=> MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz NGXQZ3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD NUfKSFhSeUiWUzDhd5NigQ>? NWnhUWpHeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM> M3vKUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NF:1XXVyUFSVIHHzd4F6 M2nRUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM> NFfifIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 M3;jOJFJXFNiYYPzZZk> NUTYcJBEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? M2Tuc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 Mn3ZdWhVWyCjc4PhfS=> NYjHSJBoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NFnHXIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NXviTnM2eUiWUzDhd5NigQ>? MnLSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{ M3nUT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH M1zGT5FJXFNiYYPzZZk> NV:xVlNUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MmfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
HCT116 NEnMdWhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NH3wWWk1QCCqcoO= NG[5UoRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gOU4zPiEQvF2u NWj4NZBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTRpPkK5OFg3QTV2PD;hQi=>
HepG2 NULqbZV3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NW\EXmVzPDhiaILz MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB4LkG3JO69VS5? NFXk[FY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2PCd-Mkm0PFY6PTR:L3G+
A549 NVTNVmkzSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M4X5elQ5KGi{cx?= M1HMd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iNj61PUDPxE1w MnW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVQoRjJ7NEi2PVU1RC:jPh?=
MCF7 Mn6wRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlrQOFghcHK| MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDZwOESg{txONg>? MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVQoRjJ7NEi2PVU1RC:jPh?=
HEK293 NEDMb|ZEgXSxdH;4bYNqfHliYYPzZZk> NE\KRmtEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgLGNQNUGGRErNRX8xODdrOzDDR|UxKGK7IHPlcIwhfmmjYnnsbZR6KGG|c3H5JIlvKESPRV2gLFExLSCIQmOpJI1m\GmjIIXzbY5oKFSFIIDsZZRmeyxiYomgVoV{[Xq3cnnuJGYpPTZyL{W5NEktKEOFNUCgQUAxNjh|NzFOwG0v NVjNdYl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzBzOUiyM{c,S2iHTVLMQE9iRg>?
Assay
Methods Test Index PMID
Western blot HIF-1α ; Akt / p-Akt / p-p70S6K ; PARP / p53 / p21 / cIAP1 / Bcl-xl / Bcl-2 ; IκBα / p-IKKα/β ; iNOS / COX-2 / Arg-1 ; Chk2 / p-Chk2 / Cyclin B1 / Cdc25c / p-Cdc25c 25383959 28388439 29040966 31053160
Immunofluorescence p21 / Nur77 28388439
Growth inhibition assay Cell viability 29040966
In vivo Celastrol (3 mg/kg) results in significant inhibition (up to 70%) of tumor growth in male nude mice bearing PC-3 tumors, associated with increased p27 levels and Bax level. Celastrol (3 mg/kg) results more apoptotic tumor cells with the appearance of various PARP cleavage fragments in tumor of male nude mice bearing PC-3 tumors. Celastrol (3 mg/kg) causes 35% of tumor inhibition, associated with decreased proteasome activity and decreased expression of AR protein in nude mice bearing C4-2B tumors. [1] Celastrol (3 mg/kg) is found to suppress strongly joint swelling and other manifestations of adjuvant arthritis in mice. Celastrol (0.2 mg/kg) significantly improves the performance in memory, learning and psychomotor activity tests in rats. [2]

Protocol (from reference)

Kinase Assay:[1]
  • Inhibition of purified 20S proteasome activity:

    A purified rabbit 20S proteasome (0.1 μg) is incubated with 40 μM of various fluorogenic peptide substrates in 100 μL assay buffer (20 mM Tris-HCl (pH 7.5)), in the presence of Celastrol at different concentrations or in the solvent DMSO for 2 hours at 37 ℃, followed by measurement of inhibition of each proteasomal activity.

Cell Research:[4]
  • Cell lines: RPMI 8226, KATOIII, UM-SCC1, U251MG and MDA-MB-231 cells
  • Concentrations: ~5 μM
  • Incubation Time: 2 hours
  • Method: The anti-proliferative effect of celastrol on various human tumor cell lines is determined by the MTT uptake method. Briefly, 5×103 cells are incubated with Celastrol in triplicate in a 96-well plate at 37 ℃. MTT solution is then added to each well. After a 2 hours incubation at 37 ℃, extraction buffer (20% SDS, 50% dimethylformamide) is added, cells are incubated overnight at 37 ℃, and the optical density is then measured at 570 nm using a Tecan plate reader.
Animal Research:[1]
  • Animal Models: nude mice bearing C4-2B tumors
  • Dosages: 3 mg/kg
  • Administration: Intraperitoneal injection

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 450.61
Formula

C29H38O4

CAS No. 34157-83-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05413226 Recruiting Dietary Supplement: Celastrol Safety Issues Legend Labz Inc. September 28 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Celastrol (NSC 70931) | Celastrol (NSC 70931) supplier | purchase Celastrol (NSC 70931) | Celastrol (NSC 70931) cost | Celastrol (NSC 70931) manufacturer | order Celastrol (NSC 70931) | Celastrol (NSC 70931) distributor